Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19

by admin | Oct 17, 2024 | Clinical Manifestations, Transmission, Epidemiology, Virus, Pathophysiology, Evidence-Based Research in Western Medicine Clinical Practice, Prevention Management, Research Materials on Influenza and Coronaviral Prevention and Treatment, Scientific reports, Vaccination, Virology, Pathophysiology

By August F. Jernbom et al.

Source Nature

Researchers found on the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients,
prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months.

An increased prevalence of new-onset autoantibodies after severe COVID-19 was found and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19.

It was found three new-onset autoantibodies associated with increased severity of neuropsychiatric symptoms post-COVID-19: anti-CALU, MYO16, and SNURF IgG.

SNURF is a small nuclear protein of unknown function, primarily expressed in brain and muscle tissues and cardiomyocytes.

Anti-SNURF IgG is highly prevalent without evidence of molecular mimicry, which may indicate epitope spreading to nuclear antigens.